← 治験一覧に戻る
進行性または転移性乳がん患者におけるGW572016
基本情報
- NCT ID
- NCT00462956
- ステータス
- 完了
- 試験のフェーズ
- 第1相
- 試験タイプ
- 介入
- 目標被験者数
- 59
- 治験依頼者名
- GlaxoSmithKline
概要
This study is designed to evaluate the efficacy and safety of GW572016 in patients with refractory breast cancer and consists of two cohorts of patients. Patients in Cohort A must have ErbB2 overexpressing tumors while patients in Cohort B must have non-ErbB2 overexpressing tumors. Patients eligible for this study must have advanced metastatic breast cancer who have previously received treatment with anthracycline and taxane.
対象疾患
Neoplasms, Breast
介入
Tykerb(DRUG)
依頼者（Sponsor）
グラクソ・スミスクライン株式会社(INDUSTRY)